Clinical and Translational Oncology

, Volume 19, Issue 3, pp 332–340 | Cite as

Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs

Research Article

Abstract

Purpose

Changes in EGFR profiles of non small cell lung cancer (NSCLC) patients correlates to clinical outcome. Extracting quality tumor tissue remains a challenge for molecular profiling. Our study aims to ascertain the clinical relevance of urinary cell free DNA as an alternative tumor material source.

Methods

150 patients with activating EGFR mutation and received EGFR-TKIs were recruited to participate in the serial monitoring study. Matched primary tumor samples were taken together with blood and urine specimens before the initiation of TKIs. The EGFR mutation testing was performed and quantified using ddPCR. For serial time point measurements, urine and blood samples were extracted at 1-month intervals for duration of 9 months.

Results

Urinary ctDNA yielded a close agreement of 88 % on EGFR mutation status when compared to primary tissue at baseline. Almost all samples detected via urine specimens were uncovered in plasma samples. Analysis of urinary cell free DNA at different time points showed a strong correlation to treatment efficacy. Interestingly, a secondary EGFR mutation T790M was detected for 53 % of the patients during monitoring. The results were corroborated with the plasma ctDNA analysis. The T790M+ group had a reduced median survival when compared to the wildtype group.

Conclusion

Urinary cell free DNA may be a potential alternative to conventional primary tissue based EGFR mutation testing. Our findings showed that the assay sensitivity was comparable to results from blood plasma. Urinary samples being noninvasive and readily available have clinical utility for monitoring of EGFR TKI treatment.

Keywords

NSCLC Cell free DNA TKI treatment Drug resistance Liquid biopsy EGFR mutations 

Supplementary material

12094_2016_1534_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 kb)

References

  1. 1.
    Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. doi:10.1126/science.1099314.CrossRefPubMedGoogle Scholar
  2. 2.
    Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42. doi:10.1016/S1470-2045(11)70184-X.CrossRefPubMedGoogle Scholar
  3. 3.
    Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81. doi:10.1038/nrc2088.CrossRefPubMedGoogle Scholar
  4. 4.
    Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Am Assoc Cancer Res. 2013;19(8):2240–7.Google Scholar
  5. 5.
    Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 2014;86(2):170–3. doi:10.1016/j.lungcan.2014.08.016.CrossRefPubMedGoogle Scholar
  6. 6.
    Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84. doi:10.1038/nrclinonc.2013.110.CrossRefPubMedGoogle Scholar
  7. 7.
    Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9(9):1345–53. doi:10.1097/JTO.0000000000000263.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O’Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20(6):1698–705.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma dna samples predict tumor response in chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol. 2009;27(16):2653–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97(6):778–84. doi:10.1038/sj.bjc.6603949.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Richardson AL, Iglehart JD. BEAMing up personalized medicine: mutation detection in blood. Clin Cancer Res. 2012;18(12):3209–11. doi:10.1158/1078-0432.CCR-12-0871.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fischbach FT, Dunning MB. A manual of laboratory and diagnostic tests. Philadelphia: Lippincott Williams & Wilkins; 2009.Google Scholar
  14. 14.
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839–43. doi:10.1148/radiology.148.3.6878708.CrossRefPubMedGoogle Scholar
  15. 15.
    Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–31. doi:10.1038/onc.2009.198.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jekunen AP. Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol. 2015;2015:11. doi:10.1155/2015/809835.CrossRefGoogle Scholar
  17. 17.
    Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990. http://www.nature.com/nm/journal/v14/n9/suppinfo/nm.1789_S1.html.
  18. 18.
    Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer. 2015;113(3):476–83. doi:10.1038/bjc.2015.225.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–50.PubMedGoogle Scholar
  20. 20.
    Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, et al. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. BioMed Res Int. 2013;2013:5. doi:10.1155/2013/270457.CrossRefGoogle Scholar
  21. 21.
    Utting M, Werner W, Dahse R, Schubert J, Junker K. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients. Am Assoc Cancer Res. 2002;8(1):35–40.Google Scholar
  22. 22.
    Su Y-H, Wang M, Brenner DE, Norton PA, Block TM. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci. 2008;1137(1):197–206. doi:10.1196/annals.1448.027.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39. doi:10.1056/NEJMoa040938.CrossRefPubMedGoogle Scholar
  24. 24.
    Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73. doi:10.1371/journal.pmed.0020073.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Liao B-C, Lin C-C. Yang JC-H. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27(2):94–101. doi:10.1097/cco.0000000000000164.CrossRefPubMedGoogle Scholar
  26. 26.
    Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016;6:20913. doi:10.1038/srep20913. http://www.nature.com/articles/srep20913-supplementary-information.
  27. 27.
    Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011;3(90):90ra59. doi:10.1126/scitranslmed.3002356.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lee Y, Lee GK, Lee Y-S, Zhang W, Hwang J-A, Nam B-H, et al. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer. 2014;120(14):2090–8. doi:10.1002/cncr.28711.CrossRefPubMedGoogle Scholar
  29. 29.
    Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.CrossRefPubMedGoogle Scholar
  30. 30.
    Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92. doi:10.1056/NEJMoa044238.CrossRefPubMedGoogle Scholar
  31. 31.
    Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–77. doi:10.1056/NEJMoa0800668.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2016

Authors and Affiliations

  1. 1.Department of Academic AffairsHubei University of MedicineShiyanChina
  2. 2.Department of OncologyXiangyang Central Hospital (The Affiliated Hospital of Hubei College of Arts and Science)XiangyangChina
  3. 3.Department of NephrologyXiangyang Central Hospital (The Affiliated Hospital of Hubei College of Arts and Science)XiangyangChina

Personalised recommendations